Pharvaris (PHVS) Profit After Tax Growth (1y) (2021 - 2026)
Powered by 
Analysis
Pharvaris (PHVS) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -8.35% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -12.04% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 94.83% |
| 10 | Pharvaris | 2.14 Bn | 1.77 Bn | 85,072.10 | -8.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.02% |
| Mar 31, 2026 | 5.85% |
| Dec 31, 2025 | -46.47% |
| Sep 30, 2025 | 5.22% |
| Jun 30, 2025 | -60.80% |
| Mar 31, 2025 | -60.14% |
| Dec 31, 2024 | -5.42% |
| Sep 30, 2024 | -78.31% |
| Jun 30, 2024 | 100.00% |
| Mar 31, 2024 | -25.31% |
| Dec 31, 2023 | 11.89% |
| Sep 30, 2023 | -200.18% |
| Jun 30, 2023 | -77.06% |
| Mar 31, 2023 | -35.04% |
| Dec 31, 2022 | -183.26% |
| Sep 30, 2022 | 20.64% |
| Jun 30, 2022 | -73,558,999.19% |
| Mar 31, 2022 | -146.77% |
| Dec 31, 2021 | -12.09% |
| Sep 30, 2021 | -44.25% |